Factor IX gene therapy - Cell Genesys

Drug Profile

Factor IX gene therapy - Cell Genesys

Alternative Names: Haemophilia B gene therapy - Cell Genesys

Latest Information Update: 07 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Genesys
  • Developer Cell Genesys; Nonindustrial source
  • Class Blood coagulation factors; Coagulants; Gene therapies
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haemophilia B

Most Recent Events

  • 04 Feb 2003 Discontinued - Preclinical for Haemophilia B in USA (IV)
  • 28 Jun 2002 Preliminary preclinical study results have been added to the pharmacodynamics section ,
  • 08 Jul 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top